Oramed Pharmaceuticals Inc represents a strong commitment to revolutionizing the treatment of diabetes. With their innovative oral insulin capsule technology, the company aims to provide a convenient and effective alternative for diabetes management. Oramed's corporate philosophy revolves around delivering cost-effective solutions that improve patients' lives and enhance treatment accessibility. By focusing on advancing oral drug delivery systems, Oramed Pharmaceuticals Inc demonstrates their dedication to transforming traditional injectable medications into easy-to-administer oral formulations. Through their cutting-edge research and development efforts, Oramed aims to address the global challenge of diabetes by offering patients a safer, more convenient, and patient-friendly approach to managing their condition.

Oramed Pharmaceuticals Inc primarily operates and has a significant presence in the United States. As a leading pharmaceutical company focused on oral drug delivery systems, Oramed Pharmaceuticals Inc offers innovative solutions for patients. With its headquarters located in Jerusalem, Israel, the company has also expanded its reach to other countries and regions worldwide. However, the United States remains the primary market where Oramed Pharmaceuticals Inc is actively engaged in advancing its breakthrough oral drug delivery technology to improve patient outcomes and transform the pharmaceutical industry.

Oramed Pharmaceuticals Inc has achieved significant milestones in its journey. The company successfully developed an innovative oral insulin capsule, ORMD-0801, which has the potential to transform diabetes treatment. Oramed also completed multiple successful clinical trials, demonstrating the efficacy and safety of their oral insulin therapy. Moreover, they obtained regulatory approvals and entered into strategic partnerships to further advance their products. Oramed's dedication towards revolutionizing diabetes care has earned them recognition and accolades within the pharmaceutical industry. With their pioneering solutions, Oramed Pharmaceuticals Inc continues to make remarkable progress in improving the lives of individuals living with diabetes.

Oramed Pharmaceuticals Inc is a prominent pharmaceutical company specializing in oral delivery systems for pharmaceutical compounds. Founded in 2006, the company is headquartered in Jerusalem, Israel. Oramed has developed innovative technology to transform injectable treatments into oral alternatives, enhancing patient convenience and adherence. Their flagship product, an oral insulin capsule, offers a groundbreaking solution for diabetes management. With a strong focus on research and development, Oramed has achieved various milestones, including successful clinical trials and partnerships with renowned organizations. Oramed Pharmaceuticals Inc continues to advance the field of oral drug delivery, offering potential for improved therapeutic options for patients worldwide.

The main competitors of Oramed Pharmaceuticals Inc in the market are companies such as Novo Nordisk, Pfizer, and Eli Lilly and Company. These pharmaceutical giants also operate in the field of diabetes management and have established themselves as key players in the global market. However, Oramed Pharmaceuticals Inc, with its innovative oral insulin delivery technology, stands out and presents a unique and promising alternative for diabetes patients. With its continued dedication to revolutionizing diabetes treatment, Oramed Pharmaceuticals Inc aims to differentiate itself and capture a significant market share in the industry.

Oramed Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Oramed Pharmaceuticals Inc. revolves around developing oral drug delivery solutions for patients. As a pharmaceutical company, Oramed focuses on the development and commercialization of oral versions of injectable drugs. By utilizing its proprietary technology, Oramed aims to improve patient convenience, compliance, and overall treatment outcomes. With a strong focus on diabetes treatment, Oramed is dedicated to delivering insulin orally. By harnessing innovative approaches, Oramed Pharmaceuticals Inc. aims to revolutionize drug delivery and improve the lives of patients worldwide.

Az Oramed Pharmaceuticals P/E mutatója -11,37.

Az Oramed Pharmaceuticals KUV 87,10.

Az AlleAktien Minőségi Score Oramed Pharmaceuticals esetében 3/10.

A várt Oramed Pharmaceuticals forgalma 1,02 Mió. USD.

A(z) várt Oramed Pharmaceuticals nyereség -7,81 Mió. USD.

Oramed Pharmaceuticals Inc is a company specialized in the development of oral drug administration. The company develops, manufactures, and markets its own medical products that focus on oral administration instead of injections. The company is headquartered in Jerusalem, Israel. The core business of Oramed Pharmaceuticals Inc is the development of oral medication products for patients with diabetes. The company is known for its groundbreaking technology for oral insulin delivery, which eliminates the need for injections for diabetics. The technology is based on the idea of delivering insulin through a capsule to the stomach, where it is absorbed through the intestinal epithelium and transported into the bloodstream. In addition to insulin delivery, the company also develops and manufactures oral medications for the treatment of osteoporosis, urinary incontinence, and other conditions. The medications are administered in the form of capsules or tablets, providing patients with a convenient alternative to traditional methods such as injections, infusions, or enemas. The company also operates a division in the field of clinical research and development. Here, the products and technologies of Oramed Pharmaceuticals Inc are tested and further developed. The company conducts clinical trials to ensure the effectiveness and safety of its medications and to obtain approval from regulatory authorities. Furthermore, the company also offers services in the area of technology licensing, product development, and drug manufacturing. Oramed Pharmaceuticals has already established strategic partnerships with other pharmaceutical companies to market its products on a global level. The business model of Oramed Pharmaceuticals Inc is based on the development and marketing of medical products that rely on technology for oral drug administration. The company pursues a growth strategy through product innovation and strategic partnerships with other industry leaders. Overall, the company offers a comprehensive range of medical products and services and pursues a clear and differentiated strategy to thrive in a competitive environment. The continuous innovation and diversification of its product portfolio also provide the company with an excellent opportunity to fully exploit the potential of its technology and strengthen growth in the future.

A(z) Oramed Pharmaceuticals évente alkalommal oszt ki 0 USD összegű osztalékot.

A Oramed Pharmaceuticals esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Oramed Pharmaceuticals ISIN kódja: US68403P2039.

A Oramed Pharmaceuticals WKN-je A1CTNU.

Az Oramed Pharmaceuticals tőzsdei rövidítése ORMP.

Az elmúlt 12 hónapban a(z) Oramed Pharmaceuticals osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Oramed Pharmaceuticals várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Oramed Pharmaceuticals jelenlegi osztalékhozama .

A(z) Oramed Pharmaceuticals negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Oramed Pharmaceuticals az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Oramed Pharmaceuticals a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Oramed Pharmaceuticals által 2025. 02. 06.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2025. 02. 06.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2025. 02. 06. időpontban történt.

2024 évben a Oramed Pharmaceuticals 0 USD összegű osztalékot fizetett ki.

Az Oramed Pharmaceuticals osztalékait USD fizeti ki.